RCT (n=737)
open-label
randomized
Yes
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Russell D. Hull (2011) conducted an RCT in venous thromboembolism (n=737). tinzaparin vs. usual care (vitamin K antagonists) was evaluated on recurrent venous thromboembolism at three months (absolute difference -0.8%, 95% CI -4.1 to 2.4).
Synapse has enriched 10 related papers. Consider them for comparative context: